Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05065515
Other study ID # KY20212109-C-1
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 1, 2021
Est. completion date December 2023

Study information

Verified date September 2022
Source Xijing Hospital
Contact Jianjun Yang, Dr
Phone 0086-13572533693
Email jianjunyang66@hotmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To explore and analyze the relationship between intestinal flora changes and the efficacy of individualized immunotherapy in patients with upper gastrointestinal cancer, and to find new biomarkers to predict the efficacy of immunotherapy, bringing new breakthroughs in tumor diagnosis and treatment.


Description:

1. Compare the composition of intestinal flora of patients before and after immunotherapy and in patients with different therapeutic effects of immunotherapy. 2. Combine the results above with the patient's blood sample, which is carried out from the metabolic level. 3. Combine the pathological data of the patient to determine the staging and pathological types, and use blood samples to detect metabolites to find out different metabolites. 4. the metabolic data and the flora data are associated with the analysis to find the bacteria species with higher correlation with the differential metabolites to guide the subsequent animal experiments.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date December 2023
Est. primary completion date October 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Age: 18-80 years old, no gender limit; 2. BMI index 18.5-23.9kg/m2; 3. Patients with esophageal squamous cell carcinoma, gastric adenocarcinoma or gastrointestinal stromal tumor diagnosed by pathology; 4. Patients who intend to undergo individualized immunotherapy, who have not undergone surgery in the past; 5. Patients with advanced or unresectable upper gastrointestinal tumors according to clinical stage; 6. ECOG score: 0-1 points; 7. Estimated survival period = 3 months; 8. All patients should have measurable or evaluable target lesions; 9. Able to eat a liquid diet or above; no complete obstruction or perforation of the digestive tract; no distant metastasis; 10. The main organs are functioning normally, that is, they meet the following standards: (1) Routine blood examination standards must meet (no blood transfusion and blood products within 14 days, no correction with G-CSF and other hematopoietic stimulating factors): 1. HB=80 g/L; 2. ANC=1.5×109/L; 3. PLT=100×109/L; (2) The biochemical inspection shall meet the following standards: a) TBIL<1.5×ULN; b) ALT and AST<2.0×ULN; c) Serum Cr=1.5×ULN or endogenous creatinine clearance> 50 mL/min (Cockcroft-Gault formula); (3) Pulmonary function assessment: Pulmonary function is normal or mild to moderately abnormal (VC%>60%, FEV1>1.2L, FEV1%>40%, DLco>40%); (4) Cardiovascular function assessment: cardiac function grade ?~?; 11. Have a certain degree of self-care ability and language comprehension ability; Exclusion Criteria: 1. Patients with pathological types and primary foci that do not meet the inclusion criteria; 2. People who are known to be allergic to macromolecular protein preparations, or to immunological preparations and contrast agents and their preparation components; 3. Risk of digestive tract perforation; 4. Evidence of distant organ metastasis; 5. Surgical treatment (except biopsy), radiotherapy, chemotherapy, and molecular targeted therapy have been performed; 6. Have suffered from other malignant tumors; 7. History of serious lung or heart disease; 8. Have active infection or have fever of unknown cause > 38.5? within 2 weeks prior to randomization (according to the judgment of the investigator, the subjects' fever due to tumor can be included in the study); 9. Significant active infection is known, or significant blood, renal, metabolic, gastrointestinal, or endocrine dysfunction is determined by the investigator; 10. A history of immunodeficiency, including HIV positive or other acquired or congenital immunodeficiency disease, or a history of organ transplantation; 11. The subject has active hepatitis B (HBV DNA = 2000 IU/mL or 104 copies/mL), hepatitis C (positive for hepatitis C antibody and hcV-RNA higher than the detection limit of analysis method); 12. Those who received live vaccine within 3 months prior to treatment; 13. Patients with acute or chronic tuberculosis infection (positive t-spot test, suspicious tuberculosis foci on chest X-ray); 14. History of drug, drug or alcohol abuse (drinking =5 times a week, =2 liang of liquor each time, etc.); 15. The patient participated in clinical trials of other antineoplastic agents within 4 weeks; 16. No intravenous infusion; 17. Severe diarrhea in the past 2 months (=3 watery stools per day for =3 days); 18. Severe constipation in the past 2 months (defecation =2 times per week, with difficulty defecating); 19. Used antibiotics for 3 days or more in the past 2 months; 20. Used proton pump stomach drugs, acid suppressants, mucosal protectants, opioid psychotropic drugs, hormones, immunosuppressants, cytotoxic drugs and other drugs within the past 2 months for 3 days or more; 21. Used probiotics, prebiotics or biosaccharides for 3 days or more in the past 2 months; 22. Abnormal thyroid function caused by cholecystitis, gastrointestinal ulcer, urinary tract infection, acute pyelonephritis, cystitis, hyperthyroidism and other diseases within the past 1 month; 23. Medical procedures such as gastrointestinal surgery, appendicitis surgery or enema or bowel cleansing have been performed within the past 1 year; 24. Lactose intolerance during pregnancy and lactation (female); 25. Patients with hypertension who cannot be reduced to the normal range by antihypertensive medication (systolic blood pressure >140 mmHg, diastolic blood pressure >90 mmHg);A history of unstable angina pectoris;Patients who were newly diagnosed with angina pectoris within 3 months before screening or had myocardial infarction within 6 months before screening;Arrhythmias (including QTcF: =450 ms for men and =470 ms for women) requiring long-term use of antiarrhythmic drugs and New York Heart Association classification =II cardiac insufficiency; 26. In the investigator's judgment, the subject has other factors that may cause him/her to be forced to terminate the study, such as other serious diseases (including mental illness) requiring combined treatment, seriously abnormal laboratory test values, family or social factors that may affect the subject's safety or the collection of test data; 27. The investigator determines other conditions that may affect the conduct of the clinical study and the determination of the study results; 28. Partners or first-degree relatives of research centre staff, researchers;

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Jianjun Yang Xi'an

Sponsors (1)

Lead Sponsor Collaborator
Xijing Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Species richness Use polymerase chain reaction (PCR) to specifically expand Increase the V3-V4 variable region of 16SrRNA and perform community analysis 6 months
Primary Degree of tumor regression We used the RECIST 1.1 evaluation criteria to evaluate the response to the immune therapy and accordingly divided patients into two groups,Response and No Response. 6 months
Secondary The relative abundance of species Use polymerase chain reaction (PCR) to specifically expand Increase the V3-V4 variable region of 16SrRNA and perform community analysis 6 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04991792 - Effect of an Infant Formula With Synbiotics in Infants Born Via Caesarean Section N/A
Completed NCT02151825 - Effect of a Synbiotic on the Gut Microbiota and Adiposity-related Markers in Healthy Overweight Subjects N/A
Completed NCT01545219 - A Study of a Prebiotic, a Probiotic and a Synbiotic Upon the Gut Microbiota and Immune Response of Healthy Volunteers N/A
Active, not recruiting NCT04435548 - Westlake Gut Microbiome Study
Enrolling by invitation NCT05057039 - The Study of Gut Microbiota in Hypertensive Patients
Not yet recruiting NCT05039060 - Modified MAC Diet and Gut Microbiota in CRC Patients N/A
Completed NCT03746158 - Interindividual Variation in Excretion of Curcumin N/A
Active, not recruiting NCT03266055 - Effects of Blueberry on Gut Microbiota and Metabolic Syndrome N/A
Completed NCT04960878 - The Effect of Synbiotics on the Upper Respiratory Tract Infection N/A
Active, not recruiting NCT05607745 - Dietary Counseling Coupled With FMT in the Treatment of Obesity and NAFLD - the DIFTOB Study N/A
Recruiting NCT04120051 - The SIMBA Project - The Effect of a Prebiotic Supplement on Glucose Metabolism and Gut Microbiota in Obese Adults N/A
Not yet recruiting NCT05481866 - Targeting Gut Microbiota and Metabolites for Very Preterm Infants Through Oropharyngeal Administration of Colostrum N/A
Completed NCT03293693 - Intake of Beta-glucan and Postprandial Regulation of Blood Glucose Metabolism in Healthy Subjects N/A
Completed NCT02207140 - Effect of Multi-species Probiotic HOWARU® Restore, on Gut Microbiota of Elderly Phase 0
Recruiting NCT04203459 - The Mechanism of Enhancing the Anti-tumor Effects of CAR-T on PC by Gut Microbiota Regulation
Active, not recruiting NCT03259685 - Effect of Non-nutritive Sweeteners of High Sugar Sweetened Beverages on Metabolic Health and Gut Microbiome N/A
Recruiting NCT06157346 - Characteristics of Intestinal Bacteria and Their Effects on Growth and Immune Function in Children at High Altitude
Completed NCT03203044 - Impact of Soylent Consumption on Human Microbiome Composition N/A
Recruiting NCT05975541 - Susceptibility to Infectious Diseases in Obesity
Active, not recruiting NCT05457439 - Sustainable-psycho-nutritional Intervention Program and Its Effects on Health Outcomes and the Environment N/A